The following story appeared on the ABC in July 2014 announcing a PBS listing. Click here to view.
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
SidebarCategory - Specialised Therapeutics - Page 22
January 11, 2014
January 8, 2014
Updated Pancreatic Cancer Data Presented at International Cancer Conference
Melbourne, January 2014 – A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1 The updated OS data from the pivotal Phase III Metastatic Pancreatic Adenocarcinoma
January 7, 2014
Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Melbourne, Australia January 7, 2014: Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc. (NASDAQ: GHDX). STA has struck an agreement to represent the important diagnostic technology
November 10, 2013
Specialised Therapeutics Australia Receives Therapeutic Goods Administration Approval for Brain Tumour Visualisation Drug – GLIOLAN®
Melbourne, Australia and Hamburg, Germany, November 2013: A novel drug which assists neurosurgeons to better visualise and remove malignant brain tumours has been approved by the Therapeutic Goods Administration (TGA). Until now, GLIOLAN (aminolevulinic acid HCl) has only been available via the Federal Government’s Special Access Scheme (SAS). It will now be made widely available for
June 8, 2013
Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation
Melbourne, June 2013 Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries. The company has become the inaugural donor for the Specialists Without Borders (SWB) organisation, an Australian based non-profit entity established in
April 26, 2013
New ‘Superbug’ Antibiotic Approved for Use in Australia
MELBOURNE, Australia – April 26, 2013 – An effective new antibiotic designed to specifically treat the common superbug* infection Clostridium difficile-associated diarrhoea will be available to patients in Australia from 14th May 2013. Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA) has received Therapeutic Goods Administration (TGA) approval to market the drug DIFICID (fidaxomicin) in Australia.
January 23, 2013
ABRAXANE® Plus Gemcitabine Improves Survival in Phase III Study of Patients with Advanced Pancreatic Cancer
MELBOURNE, Australia – January 23, 2013 – Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving
November 8, 2012
ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study
Melbourne, November 2012 Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. This is now the fourth disease in which ABRAXANE has demonstrated positive phase III results,
October 25, 2012
ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
MELBOURNE, Australia – October 25, 2012 – Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel).
October 15, 2012
Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
Lugano, Switzerland and Melbourne, Australia, October 15th, 2012 – Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company Helsinn Healthcare to in-license the novel ghrelin receptor agonist anamorelin for both Australia and New Zealand.